Nano co-delivery of doxorubicin and plumbagin achieves synergistic chemotherapy of hepatocellular carcinoma
Authors:
- 4 July 2024
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 661, 124424
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82074154)
- National Natural Science Foundation of China (82222074)
- Shanghai Municipal Education Commission (23SG38)
- Department of Science and Technology of Jilin Province (20230101170JC)
- Department of Science and Technology of Jilin Province (20230402044GH)
- Department of Science and Technology of Jilin Province (20240305083YY)
This publication has 44 references indexed in Scilit:
- Nanoformulations of chemotherapeutic activators of the cGAS–STING pathway in tumor chemoimmunotherapyDrug Discovery Today, 2024
- Nano Delivery of Chemotherapeutic ICD Inducers for Tumor ImmunotherapySmall Methods, 2023
- Apigenin alleviates resistance to doxorubicin in breast cancer cells by acting on the JAK/STAT signaling pathwayMolecular Biology Reports, 2022
- Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective managementBiomedicine & Pharmacotherapy, 2021
- A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancerActa Pharmaceutica Sinica B, 2021
- Nanodelivery of immunogenic cell death-inducers for cancer immunotherapyDrug Discovery Today, 2021
- Membrane-core nanoparticles for cancer nanomedicineAdvanced Drug Delivery Reviews, 2020
- Polymer degradation and drug delivery in PLGA‐based drug–polymer applications: A review of experiments and theoriesJournal of Biomedical Materials Research Part B: Applied Biomaterials, 2016
- Nanoparticles with Precise Ratiometric Co‐Loading and Co‐Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder CancerAdvanced Functional Materials, 2014
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984